SM17
What stands out
- Monoclonal antibody
- Injection every 2 weeks in trials
Derived from NCT07466940 · NCT07103369 · This is a summary of public records for informational purposes only. It is not medical advice.
History
Earliest recorded event: Nov 21, 2023. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.
- Mar 31, 2026Phase 2 trial startedA Clinical Study to Evaluate SM17 for Atopic Dermatitis ClinicalTrials.gov NCT07445919
- Feb 3, 2026Phase 1 trial completed · Eczema target not confirmedA Clinical Study to Evaluate SM17 in Healthy Participants ClinicalTrials.gov NCT07466940
- Oct 14, 2025Phase 1 trial started · Eczema target not confirmedA Clinical Study to Evaluate SM17 in Healthy Participants ClinicalTrials.gov NCT07466940
- Mar 31, 2025Phase 1 trial completedA Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT07103369
- Mar 24, 2025Phase 1 main data collectedA Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT07103369
- Nov 21, 2023Phase 1 trial startedA Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT07103369